Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of 4.55% and 34.78%, respectively, for the quarter ended September 2022. Do…
9,075€
-0,82%
Echtzeit-Aktienkurs Theravance Biopharma Inc.
Bid:
Ask:
Nachrichten zur Theravance Biopharma Inc. Aktie
Theravance Biopharma Q3 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System
DUBLIN, Oct. 25, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine…